They looked at carpal tunnel surgery and asked the inconvenient question: why does fixing a small problem require such a large cut?
In an exam room - not an operating theater - a hand surgeon presses an ultrasound probe to a wrist, watches the median nerve appear on a screen, and through an opening a few millimeters wide, releases the ligament that has been pinching it. The patient drives home. There are no stitches to remove.
That room is the whole argument for Sonex Health. The company makes the devices that turn carpal tunnel release - one of the most common surgical procedures in the United States - into something closer to an office visit than an operation. No large incision. No general anesthesia. No six-week wait while the palm heals around a scar. The surgeon sees the anatomy in real time and works inside the lines that ultrasound draws for them.
It is a quiet kind of company. It does not sell an app, a subscription, or a promise about artificial intelligence. It sells single-use instruments named with engineer-brained literalness - UltraGuideCTR, UltraGuideTFR - and a belief that the most useful innovation in medicine is sometimes a smaller hole.
Carpal tunnel syndrome is unglamorous and everywhere. It is the tingling hand of the office worker, the numb fingers of the assembly-line operator, the ache that wakes people at 3 a.m. The standard fix - open or endoscopic release - works. It also tends to involve an operating room, sometimes general anesthesia, a real incision, and a recovery measured in weeks. For a problem this routine, the overhead always looked a little absurd.
The catch is precision. Inside the wrist sits the median nerve and a crowd of vessels you very much do not want to nick. Traditional minimally invasive attempts struggled with the same tradeoff: cut smaller and you also see less. For decades, surgeons accepted the larger incision partly as the price of being able to look at what they were doing.
Less invasive usually meant less visibility. More visibility usually meant a bigger cut. Sonex's founders refused to accept that the two had to move in opposite directions.
In 2014, two Mayo Clinic physicians - Darryl Barnes, MD and Jay Smith, MD - made a bet alongside operations partner Aaron Keenan. Their wager: if you give a surgeon a clear, real-time ultrasound view of the carpal tunnel, you no longer need the big incision to stay safe. You can have visibility and a tiny opening at the same time. The device that became UltraGuideCTR started life under the less-marketable name “SX-One Micro-Knife.”
Barnes was not new to this. He holds a stack of device patents, and earlier inventions of his were licensed to other medtech firms. Smith brought the clinical and ultrasound expertise. The combination - inventor, clinician, operator - is the unglamorous formula behind a lot of medical devices that actually reach patients instead of conference posters.
The bet had a five-year fuse. UltraGuideCTR cleared the FDA in 2019, and the idea moved from Mayo workshop to commercial product. The company's design philosophy has a name - “refined simplicity” - which is the polite way of saying they kept removing parts until only the necessary ones were left.
The product line is narrow on purpose. Each device pairs a cutting element with components that protect the structures you must not touch, all of it designed to work under live ultrasound. The result is a procedure a surgeon can perform in the office, through an incision small enough that “scar” feels like an overstatement.
FDA-cleared in 2019. Releases the transverse carpal ligament under real-time ultrasound through a tiny opening.
Full market release in 2022. Brings the same ultrasound-guided approach to the locked, catching trigger finger.
The small parts that keep the nerve and vessels out of harm's way while the ligament is cut.
Cadaver courses and web-based training so surgeons learn the ultrasound technique before they ever pick up the device.
If a surgeon can see the anatomy on ultrasound, they can release it through an opening that barely qualifies as a cut. Everything Sonex builds is downstream of that sentence.
Mayo Clinic physicians Darryl Barnes and Jay Smith, with operator Aaron Keenan, start Sonex Health in Minnesota.
The carpal tunnel device moves from idea to approved product.
Full market release of the trigger finger device extends the approach to a second condition.
KCK MedTech leads a $40M round; the company marks more than 20,000 carpal tunnel patients treated.
First patient enrolled in a real-world registry comparing release techniques head to head.
MISSION reaches its enrollment goal - 1,300+ patients across 33 sites in 18 months.
A medtech founder can claim almost anything. The skeptic's only real questions are: how many patients, and what does the evidence say? Sonex has spent heavily on the second part - building one of the largest clinical-evidence programs in its category rather than leaning on testimonials.
The 2025 MISSION milestone matters precisely because Sonex did not design it to flatter itself. The registry compares ultrasound-guided release against endoscopic and open approaches in the real world - the kind of head-to-head data that a company only commissions when it thinks it can win.
Hand surgeons, orthopedic surgeons, and physical medicine physicians running office-based practices. The business is classic B2B medtech: single-use devices, disposables, training, and the clinical evidence that lets a surgeon justify switching techniques.
The stated goal is to be a world leader in ultrasound-guided surgery - to deliver therapies that are less invasive, safer, and cheaper than what came before. Read past the medtech phrasing and it is a single ambition: make ultrasound-guided release the default, not the alternative. The company is not trying to win a niche. It is trying to move the floor.
That is also why the evidence spending makes sense. “Standard of care” is not a marketing line you can buy - it is a verdict that surgeons, payers, and guidelines hand down slowly, on the strength of data. Sonex is playing a long game where the prize is being boring: the obvious, default choice that nobody argues about anymore.
Carpal tunnel and trigger finger are only the opening move. The harder claim underneath Sonex Health is that a lot of orthopedic surgery still happens in expensive rooms, under bright lights, simply because that is how it has always happened. If real-time ultrasound can guide a safe release in an exam chair, the question stops being about one ligament and starts being about how much of surgery's overhead is tradition rather than necessity.
Healthcare loves to promise transformation and deliver a slightly better portal. Sonex's wager is smaller and more credible: take a procedure millions of people will need, and quietly remove the parts that were never doing the patient any good - the big room, the long scar, the lost weeks.
So picture the room again. A wrist. A probe. A screen showing the nerve. A few minutes, an opening barely worth a bandage, and a patient who drives home and forgets it happened. That used to be a surgery. Sonex Health spent eleven years making it look like an appointment.